Cargando…

Iranian clinical practice guideline for amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegeneration involving motor neurons. The 3–5 years that patients have to live is marked by day-to-day loss of motor and sometimes cognitive abilities. Enormous amounts of healthcare services and resources are necessary to support pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Boostani, Reza, Olfati, Nahid, Shamshiri, Hosein, Salimi, Zanireh, Fatehi, Farzad, Hedjazi, Seyed Arya, Fakharian, Atefeh, Ghasemi, Majid, Okhovat, Ali Asghar, Basiri, Keivan, Haghi Ashtiani, Bahram, Ansari, Behnaz, Raissi, Gholam Reza, Khatoonabadi, Seyed Ahmadreza, Sarraf, Payam, Movahed, Sara, Panahi, Akram, Ziaadini, Bentolhoda, Yazdchi, Mohammad, Bakhtiyari, Jalal, Nafissi, Shahriar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272856/
https://www.ncbi.nlm.nih.gov/pubmed/37333000
http://dx.doi.org/10.3389/fneur.2023.1154579
_version_ 1785059591519731712
author Boostani, Reza
Olfati, Nahid
Shamshiri, Hosein
Salimi, Zanireh
Fatehi, Farzad
Hedjazi, Seyed Arya
Fakharian, Atefeh
Ghasemi, Majid
Okhovat, Ali Asghar
Basiri, Keivan
Haghi Ashtiani, Bahram
Ansari, Behnaz
Raissi, Gholam Reza
Khatoonabadi, Seyed Ahmadreza
Sarraf, Payam
Movahed, Sara
Panahi, Akram
Ziaadini, Bentolhoda
Yazdchi, Mohammad
Bakhtiyari, Jalal
Nafissi, Shahriar
author_facet Boostani, Reza
Olfati, Nahid
Shamshiri, Hosein
Salimi, Zanireh
Fatehi, Farzad
Hedjazi, Seyed Arya
Fakharian, Atefeh
Ghasemi, Majid
Okhovat, Ali Asghar
Basiri, Keivan
Haghi Ashtiani, Bahram
Ansari, Behnaz
Raissi, Gholam Reza
Khatoonabadi, Seyed Ahmadreza
Sarraf, Payam
Movahed, Sara
Panahi, Akram
Ziaadini, Bentolhoda
Yazdchi, Mohammad
Bakhtiyari, Jalal
Nafissi, Shahriar
author_sort Boostani, Reza
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegeneration involving motor neurons. The 3–5 years that patients have to live is marked by day-to-day loss of motor and sometimes cognitive abilities. Enormous amounts of healthcare services and resources are necessary to support patients and their caregivers during this relatively short but burdensome journey. Organization and management of these resources need to best meet patients' expectations and health system efficiency mandates. This can only occur in the setting of multidisciplinary ALS clinics which are known as the gold standard of ALS care worldwide. To introduce this standard to the care of Iranian ALS patients, which is an inevitable quality milestone, a national ALS clinical practice guideline is the necessary first step. The National ALS guideline will serve as the knowledge base for the development of local clinical pathways to guide patient journeys in multidisciplinary ALS clinics. To this end, we gathered a team of national neuromuscular experts as well as experts in related specialties necessary for delivering multidisciplinary care to ALS patients to develop the Iranian ALS clinical practice guideline. Clinical questions were prepared in the Patient, Intervention, Comparison, and Outcome (PICO) format to serve as a guide for the literature search. Considering the lack of adequate national/local studies at this time, a consensus-based approach was taken to evaluate the quality of the retrieved evidence and summarize recommendations.
format Online
Article
Text
id pubmed-10272856
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102728562023-06-17 Iranian clinical practice guideline for amyotrophic lateral sclerosis Boostani, Reza Olfati, Nahid Shamshiri, Hosein Salimi, Zanireh Fatehi, Farzad Hedjazi, Seyed Arya Fakharian, Atefeh Ghasemi, Majid Okhovat, Ali Asghar Basiri, Keivan Haghi Ashtiani, Bahram Ansari, Behnaz Raissi, Gholam Reza Khatoonabadi, Seyed Ahmadreza Sarraf, Payam Movahed, Sara Panahi, Akram Ziaadini, Bentolhoda Yazdchi, Mohammad Bakhtiyari, Jalal Nafissi, Shahriar Front Neurol Neurology Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegeneration involving motor neurons. The 3–5 years that patients have to live is marked by day-to-day loss of motor and sometimes cognitive abilities. Enormous amounts of healthcare services and resources are necessary to support patients and their caregivers during this relatively short but burdensome journey. Organization and management of these resources need to best meet patients' expectations and health system efficiency mandates. This can only occur in the setting of multidisciplinary ALS clinics which are known as the gold standard of ALS care worldwide. To introduce this standard to the care of Iranian ALS patients, which is an inevitable quality milestone, a national ALS clinical practice guideline is the necessary first step. The National ALS guideline will serve as the knowledge base for the development of local clinical pathways to guide patient journeys in multidisciplinary ALS clinics. To this end, we gathered a team of national neuromuscular experts as well as experts in related specialties necessary for delivering multidisciplinary care to ALS patients to develop the Iranian ALS clinical practice guideline. Clinical questions were prepared in the Patient, Intervention, Comparison, and Outcome (PICO) format to serve as a guide for the literature search. Considering the lack of adequate national/local studies at this time, a consensus-based approach was taken to evaluate the quality of the retrieved evidence and summarize recommendations. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272856/ /pubmed/37333000 http://dx.doi.org/10.3389/fneur.2023.1154579 Text en Copyright © 2023 Boostani, Olfati, Shamshiri, Salimi, Fatehi, Hedjazi, Fakharian, Ghasemi, Okhovat, Basiri, Haghi Ashtiani, Ansari, Raissi, Khatoonabadi, Sarraf, Movahed, Panahi, Ziaadini, Yazdchi, Bakhtiyari and Nafissi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Boostani, Reza
Olfati, Nahid
Shamshiri, Hosein
Salimi, Zanireh
Fatehi, Farzad
Hedjazi, Seyed Arya
Fakharian, Atefeh
Ghasemi, Majid
Okhovat, Ali Asghar
Basiri, Keivan
Haghi Ashtiani, Bahram
Ansari, Behnaz
Raissi, Gholam Reza
Khatoonabadi, Seyed Ahmadreza
Sarraf, Payam
Movahed, Sara
Panahi, Akram
Ziaadini, Bentolhoda
Yazdchi, Mohammad
Bakhtiyari, Jalal
Nafissi, Shahriar
Iranian clinical practice guideline for amyotrophic lateral sclerosis
title Iranian clinical practice guideline for amyotrophic lateral sclerosis
title_full Iranian clinical practice guideline for amyotrophic lateral sclerosis
title_fullStr Iranian clinical practice guideline for amyotrophic lateral sclerosis
title_full_unstemmed Iranian clinical practice guideline for amyotrophic lateral sclerosis
title_short Iranian clinical practice guideline for amyotrophic lateral sclerosis
title_sort iranian clinical practice guideline for amyotrophic lateral sclerosis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272856/
https://www.ncbi.nlm.nih.gov/pubmed/37333000
http://dx.doi.org/10.3389/fneur.2023.1154579
work_keys_str_mv AT boostanireza iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT olfatinahid iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT shamshirihosein iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT salimizanireh iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT fatehifarzad iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT hedjaziseyedarya iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT fakharianatefeh iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT ghasemimajid iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT okhovataliasghar iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT basirikeivan iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT haghiashtianibahram iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT ansaribehnaz iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT raissigholamreza iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT khatoonabadiseyedahmadreza iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT sarrafpayam iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT movahedsara iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT panahiakram iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT ziaadinibentolhoda iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT yazdchimohammad iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT bakhtiyarijalal iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis
AT nafissishahriar iranianclinicalpracticeguidelineforamyotrophiclateralsclerosis